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PTime Is Muscle
Translation Into Practice
Elliott M. Antman, MD, FACC
Boston, Massachusetts
In the future, advances in the care of patients with ST-segment elevation myocardial infarction (STEMI) will not
come from the analysis of trials that do not reflect current practice in an effort to rationalize extending the per-
cutaneous coronary intervention (PCI)-related delay time. We must move beyond such arguments and find ways
to shorten total ischemic time. With the launching of the American College of Cardiology’s D2B Alliance and the
American Heart Association’s Mission: Lifeline programs, the focus is now on systems improvement for reperfu-
sion in patients with STEMI. The D2B Alliance was developed to focus on improvement in door-to-balloon times
for patients with STEMI who are undergoing primary PCI. The American Heart Association Mission: Lifeline pro-
gram is a broad, comprehensive national initiative to improve the quality of care and outcomes of patients with
STEMI by improving health care system readiness and response to STEMI. Improvements in access to timely
care for patients with STEMI will require a multifaceted approach involving patient education, improvements in
the Emergency Medical Services and emergency department components of care, the establishment of net-
works of STEMI-referral hospitals (not PCI capable) and STEMI-receiving hospitals (PCI capable), as well as coor-
dinated advocacy efforts to work with payers and policy makers to implement a much-needed health care sys-
tem redesign. By focusing now on system efforts for improvements in timely care for STEMI, we will complete
the cycle of research initiated by Reimer and Jennings 30 years ago. Time is muscle . . . we must translate that
into practice. (J Am Coll Cardiol 2008;52:1216–21) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.011n
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Civen the urgency of reperfusion of the occluded infarct
rtery in patients with ST-segment elevation myocardial
nfarction (STEMI), it is not unexpected that the most
requently discussed aspects of management are the selec-
ion and implementation of a reperfusion strategy. Despite
he importance of these topics, when attempting to write
uidelines for management of STEMI, clinicians should
ealize that the “evidence” on which to base such recom-
endations is derived from databases that do not com-
letely answer all of our questions.
For example, a frequently quoted overview by Keeley
t al. (1) in which they compare fibrinolytic reperfusion with
atheter-based reperfusion summarizes the experience from
total of only 7,739 patients enrolled collectively in 23
andomized trials. These 23 trials have publication dates
anging from 1990 to 2002, raising questions about their
ontemporary relevance because of shifts in the use of other
ffective therapies besides the exact mode of reperfusion for
TEMI.
Furthermore, the largest difference in absolute event rates
etween pharmacologic and catheter-based reperfusion was
n recurrent infarction (something that is difficult to diag-
rom the TIMI Study Group, Cardiovascular Division, Brigham and Women’s
ospital, Boston, Massachusetts.t
Manuscript received June 4, 2008; revised manuscript received July 2, 2008,
ccepted July 11, 2008.ose accurately in the setting of primary percutaneous
oronary intervention [PCI] for STEMI); the differences in
ortality and hemorrhagic stroke, although still favoring
hose patients undergoing primary PCI, were much more
odest. Contemporary attempts by researchers to merge the
reperfusion strategies in the form of facilitated PCI (a
reparatory pharmacologic regimen followed at varying
imes by PCI) have not shown this approach to be an
ttractive one—there is no clear reduction in mortality or
einfarction with facilitated PCI, and concerns exist about a
efinite increase in the risk of bleeding (2–4).
Despite the deficiencies in the evidence base, it is gener-
lly accepted that primary PCI is the preferred mode of
eperfusion, provided it can be delivered in a timely fashion
y an experienced operator (75 PCI procedures/year) and
eam (at least 200 PCI procedures per year, including at
east 36 primary PCI procedures/year) (5). The issue centers
n what is meant by a “timely fashion.” Because in virtually
ll cases there is an inherent delay in implementation of a
rimary PCI strategy, many analyses have been performed
o provide guidance on the acceptable delays to primary
CI—the metric “door-to-balloon” (D2B) time arose and
as initially proposed to be 120 min.
By 2004, several pieces of evidence had emerged that led
o a shortening of the recommended D2B time to 90 min.
oncern arose that long delays to primary PCI run countero the guiding principle that “time is muscle,” as shown by
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October 7, 2008:1216–21 Time Is Muscleeimer and Jennings nearly 30 years ago (6). Investigators
nderstood that the amount of myocardial salvage per unit
ime from the moment of coronary occlusion is not linear
ut rather curvilinear with the maximum amount of salvage
n the first few hours after the onset of infarction, with sharp
eductions in the amount of salvage thereafter as each hour
asses (7).
Thus, total ischemic time is of paramount importance
nd often is overlooked in discussions about time to reper-
usion. The importance of total ischemic time holds true
egardless of whether reperfusion is attempted with a
brinolytic or by PCI (8,9). Clinical trials in Europe testing
he strategy of transfer of STEMI patients from community
ospitals to PCI centers (10,11) consistently showed lower
ortality in the transfer patients but also showed that it was
ossible to implement the PCI strategy within 90 min from
andomization—giving birth to the recommendations in
004 on both sides of the Atlantic that the system goal
hould be to perform primary PCI within 90 min of the first
edical contact (preferably the Emergency Medical Services
EMS] team in patients who call 911 [EMS-to-balloon 
0 min], but D2B should comprise 90 min in those patients
hose first medical contact is the door of the hospital)
5,12).
Several authors have argued that the benefits of primary
CI compared with fibrinolytic therapy extend well beyond
he 90-min window noted previously (13). Claims have
een published that the benefit of primary PCI is still
bserved even if there is a 3-h delay compared with the time
hen a fibrinolytic could be administered (14). In a patient-
evel analysis from 22 trials (total sample size  6,763) that
argely overlaps with the Keeley et al. (1) overview noted
reviously in this commentary, Boersma (15) concluded that
rimary PCI was associated with a lower 30-day mortality
ompared with fibrinolytic therapy regardless of the PCI-
elated delay time (a hospital-level factor).
It is hard to accept the argument that PCI-related delay
ime does not matter at all both on a biologic basis and also
n a statistical basis. A particularly concerning observation
n the Boersma meta-analysis (15) is the finding of an
nusual relationship between the 30-day mortality and
CI-related delay time. Although there is the expected
ncrease in mortality with longer delays to PCI in patients
llocated to PCI, a biologically implausible pattern was
bserved in those allocated to fibrinolysis. The 30-day
ortality in the fibrinolytic group was 8.2% when the
CI-related delay compared with fibrinolysis was 0 to 35
in, decreased to 6.8% when it was 35 to 50 min,
ecreased further to 5.4% when it was 50 to 62 min,
ncreased abruptly to 9.5% when it was 62 to 79 min, and
hen remained at 9.6% when it was 79 to 120 min. Why
hould the efficiency with which a hospital can implement a
rimary PCI strategy have any bearing on the mortality rate
hen patients receive a fibrinolytic (16)?
Another difficulty with the Boersma meta-analysis (15) ishe under-representation of patients with a relatively short (resentation delay. Pre-hospital
brinolysis, which helps reduce
otal ischemic time, is an impor-
ant treatment consideration in
uch patients, given the much
horter time to initiation of a
eperfusion strategy compared
ith the time delay to implement
rimary PCI (17,18). When pre-
ospital lysis is combined with
he aggressive use of rescue PCI,
-year mortality appears compa-
able with that achieved with pri-
ary PCI (19,20).
Other attempts to estimate the
ime tradeoff between fibrinolysis and primary PCI suggest
hat the mortality benefit of primary PCI is lost if it is
elayed by more than 60 min compared with a fibrin-
pecific lytic; when one adds the door-to-needle time of 30
in for a lytic, further support is found for the recommen-
ation of a D2B time of 90 min (21,22). Indeed, as
uggested by Pinto et al. (23), the situation is much more
omplex than can be represented by a single number. Using
large dataset from NRMI (National Registry of Myocar-
ial Infarction), Pinto et al. (23) showed that the equipoise
oint between primary PCI and a fibrinolytic may be as
ittle as 40 min in a high-risk situation with much myocar-
ium to salvage when one factors in the time from onset of
ymptoms, age of the patient, and location of the infarction
e.g., early presentation after the onset of infarction in a
oung patient with an anterior infarction); it may extend to
79 min in other situations (late presentation in an elderly
atient with a nonanterior infarction) (23). These points
mphasize, as stated in the preamble to STEMI clinical
ractice guidelines, that the recommendations put forward
y writing committees are system goals but are not meant to
upersede clinician judgment in individual cases.
The latest discussion about the 90-min system goal for
mplementing primary PCI is in this issue of the Journal by
erkelsen et al. (24), who ask, “Is there any time left for
rimary PCI according to the 2007 Updated American
ollege of Cardiology (ACC)/American Heart Association
AHA) STEMI Guidelines and the D2B Alliance?” (24).
heir interpretation of the 2007 ACC/AHA STEMI
uidelines is that the Writing Committee advocates what
mounts to a PCI-related delay of only 40 min, and they ask
hat consideration be given to extending the D2B time back
o 120 min.
To buttress their argument, Terkelsen et al. (24) cite
uch of the information discussed previously in this com-
entary and place emphasis on the Boersma meta-analysis
15) without commenting on the problems noted in a key
gure, which they reproduced. In their Figure 1, Terkelsen
t al. (24) also use unrealistically short transfer times that are
ot representative of experience in large parts of the U.S.
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
D2B  door-to-balloon
EMS  Emergency Medical
Services
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction5,24,25). The D2B time of 30 min proposed by Terkelsen
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Time Is Muscle October 7, 2008:1216–21t al. (24) in the “rerouting” strategy for STEMI (option C
n their Fig. 1), although potentially achievable, requires a
ighly integrated pre-hospital notification system to alert
he catheterization team while the patient is being trans-
orted—a laudable goal but not yet achieved in most parts
f the U.S.
It appears that Terkelsen et al. (24) only focused on
elective sentences in the text of Section 6.3.1.6: Reperfu-
ion of the 2007 Update to the STEMI Guideline (26).
hey argue, without providing data, that the typical pre-
ospital delay includes 10 min at the scene and 10 min for
ransportation. By subtracting these 20 min from the
ifference in the recommendation of EMS-to-balloon of 90
Figure 1 Options for Transportation of STEMI Patients and Initi
Reperfusion in patients with STEMI can be accomplished by pharmacological (fibrin
total ischemic time within 120 min (ideally within 60 min) from symptom onset to
medical system based on the mode of patient transportation and the capabilities
treatment of patients with STEMI so that door-to-needle (or medical contact-to-nee
(or medical contact-to-balloon) for PCI can be achieved within 90 min. These goals
be considered acceptable for a given system. Systems that are able to achieve ev
cal system goals: EMS transport (recommended): 1. If EMS has fibrinolytic capabi
within 30 min of arrival of EMS on the scene; 2. If EMS is not capable of administ
pital, the door-to-needle time should be within 30 min for patients for whom fibrino
and the patient is transported to a PCI-capable hospital, the EMS arrival-to-balloon
tal, it is appropriate to consider emergency interhospital transfer of the patient to
fibrinolysis; PCI can be initiated promptly within 90 min from EMS arrival-to-balloon
(i.e., “rescue PCI”). Patient self-transport (discouraged): 1. If the patient arrives at
at the emergency department; 2. If the patient arrives at a PCI-capable hospital, th
PCI-capable hospital, it is appropriate to consider emergency interhospital transfer
PCI can be initiated within 90 min after the patient presented to the initial receivin
could be initiated at the initial receiving hospital; or fibrinolysis is administered an
of EMS arrival on scene” after the patient calls EMS/911 or “time of arrival at the
the patient transports himself/herself to the hospital. Source: Figure 1 in Antman 
capable hospital to transfer to PCI-capable hospital¡Arrival at PCI-capable hospita
coronary intervention; STEMI  ST-segment elevation myocardial infarction.in and door-to-needle time of 30 min, they conclude that ehe Writing Committee was only allowing a PCI-related
elay of 40 min. Their conclusion is not correct and does
ot reflect the spirit and intent of the Writing Committee,
or is it consistent with the wording of the recommenda-
ions or the algorithm that is clearly described in Figure 1,
ummarizing the options for transportation of STEMI
atients and initial reperfusion treatment goals.
Most EMS systems in the U.S. do not have teams trained
n the administration of pre-hospital fibrinolysis for
TEMI. Recognizing this fact, the Writing Committee
mphasized that the system goal is to deliver the drug
ithin 30 min of the time the patient presents to the door
f the hospital. Also noting that a critical component of
perfusion Treatment Goals
) or catheter-based (primary PCI) approaches. The overarching goal is to keep
on of reperfusion treatment. Within this context, the following are goals for the
receiving hospital. The medical system goal is to facilitate rapid recognition and
r initiation of fibrinolytic therapy can be achieved within 30 min or door-to-balloon
d not be understood as “ideal” times but rather the longest times that should
re rapid times for treatment of patients with STEMI should be encouraged. Medi-
the patient qualifies for therapy, pre-hospital fibrinolysis should be started
pre-hospital fibrinolysis and the patient is transported to a non–PCI-capable hos-
s indicated; 3. If EMS is not capable of administering pre-hospital fibrinolysis
should be within 90 min; 4. If EMS takes the patient to a non–PCI-capable hospi-
apable hospital for mechanical revascularization if: there is a contraindication to
at the PCI-capable hospital*; or fibrinolysis is administered and is unsuccessful
–PCI-capable hospital, the door-to-needle time should be within 30 min of arrival
r-to-balloon time should be within 90 min; 3. If the patient presents to a non–
patient to a PCI-capable hospital if: there is a contraindication to fibrinolysis;
pital or within 60 min compared with when fibrinolysis with a fibrin-specific agent
successful (i.e., “rescue PCI”). Note that “medical contact” is defined as “time
gency department door” (whether PCI-capable or non–PCI-capable hospital) when
(26). *EMS Arrival¡Transport to non–PCI-capable hospital¡Arrival at non–PCI-
lloon time  90 min. EMS  emergency medical system; PCI  percutaneousal Re
olysis
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October 7, 2008:1216–21 Time Is Musclectivation of the catheterization lab (including from the
mbulance en route to the PCI center), the Writing Com-
ittee emphasized a system goal of primary PCI within 90
in of first medical contact.
The system goal for hospitals without PCI capability was
ept at a door-to-needle time for fibrinolysis to reflect
urrent practice. However, as clearly stated in the text, “This
ommittee continues to endorse the concept that faster
imes to reperfusion and better systems of care are associated
ith important reductions in morbidity and mortality rates
n patients with STEMI. An underused but effective strat-
gy for improving systems of care for STEMI patients is to
xpand the use of pre-hospital 12-lead electrocardiography
rograms by emergency medical systems (EMS) that pro-
ide advanced life support” (33,34). In addition, “The
riting group does believe that every effort should be made
o reduce the time from first medical contact to fibrinolytic
herapy when that is considered the appropriate reperfusion
trategy.” The exact wording of the current recommenda-
ions is shown in Table 1. The Writing Committee reiter-
ted in Figure 1 that EMS transport is the recommended
ethod of transport and clearly stated in the legend to
igure 1 (26) that 1) If EMS has fibrinolytic capability and
he patient qualifies for therapy, pre-hospital fibrinolysis
hould be started within 30 min of arrival of EMS on the
cene; 2) if EMS is not capable of administering pre-
ospital fibrinolysis and the patient is transported to a
on–PCI-capable hospital, the door-to-needle time should
e within 30 min for patients for whom fibrinolysis is
ndicated; and 3) if EMS is not capable of administering
re-hospital fibrinolysis and the patient is transported to a
CI-capable hospital, the EMS arrival-to-balloon time
hould be within 90 min.
Advances in the care of patients with STEMI in the
uture will not come from analysis of trials that do not
eflect current practice in an effort to rationalize extending
he PCI-related delay time (24). We must move beyond
uch arguments and find ways to shorten total ischemic
ime. We need to focus on translational research in the sense
escribed by Woolf (27)—“. . . ensuring that new treat-
ents and research knowledge actually reach the patients or
opulations for whom they are intended and are imple-
ented correctly.” The way forward for transformation of
eperfusion for STEMI will come from the kind of thinking
007 STEMI Focusedpdate Recommendation: Class I
Table 1 2007 STEMI FocusedUpdate Recommendation: Class I
1. STEMI patients presenting to a hospital with PCI capability should be treated
with primary PCI within 90 min of first medical contact (Fig. 1) as a systems
goal. (Level of Evidence: A)
2. STEMI patients presenting to a hospital without PCI capability and who cannot
be transferred to a PCI center and undergo PCI within 90 min of first medical
contact (Fig. 1) should be treated with fibrinolytic therapy within 30 min of
hospital presentation as a systems goal unless fibrinolytic therapy is
contraindicated. (Level of Evidence: B)L
odified from Antman et al. (26).
PCI percutaneous coronary intervention; STEMI ST-segment elevationmyocardial infarction.escribed by Dougherty and Conway (28), who outlined the
3 T’s” road map to improve U.S. health care (Table 2).
We have acquired a rich database of clinical trials that
rame our understanding of the clinical efficacy of fibrino-
ysis and primary PCI for reperfusion in STEMI (T1 phase
f the road map in Table 2). Cardiologists have been leaders
n internal medicine by participation in registries such as
RMI, NCDR (National Cardiovascular Data Registry),
AP (Guidelines Applied in Practice), and GWTG (Get
ith the Guidelines). The latest of these is the newly
ormed ACTION (Acute Coronary Treatment and Inter-
ention Outcomes Network)-GWTG Registry as a joint
ffort of the ACC and AHA. Registry efforts form the T2
hase of the road map and provide much-needed informa-
ion regarding outcomes and clinical effectiveness (Table 2).
e have now entered the T3 phase of the road map with
ajor efforts at systems improvement for reperfusion in
TEMI by the launching of the ACC’s D2B Alliance
nd the AHA’s Mission: Lifeline programs (Table 2)
29,30). The Danish core strategies proposed by Ter-
elsen et al. (24) to reduce system delay in all STEMI
atients are a highly commendable effort in this regard
nd are already being addressed in the AHA’s Mission:
oad Map for Transformationf Reperfusion Therapy for STEMI
Table 2 Road Map for Transformationof Reperfusion Therapy for STEMI
Translational
Step
Key Aspects of
Translational Step Reperfusion for STEMI
1 Activity to test what care
works:
● Clinical efficacy
research
Randomized clinical trials of
fibrinolysis and catheter-
based therapies
2 Activities to test who
benefits from
providing care:
● Outcomes research
● Comparative
effectiveness
research
● Health services
research
Registries such as the joint
ACC/AHA ACTION-GWTG
Registry
3 Activities to test how to
deliver high-quality
care reliably and in all
settings:
ACC D2B Alliance
● Measurement and
accountability of
health care quality
and cost
● Implementation of
interventions and
health care system
redesign
● Scaling and spread of
effective interventions
● Research in above
domains
AHA Mission: Lifeline
dapted from information in Dougherty and Conway (28).
ACC  American College of Cardiology; ACTION  Acute Coronary Treatment and Intervention
utcomes Network; AHA American Heart Association; D2B door-to-balloon; GWTG Get With
he Guidelines; other abbreviation as in Table 1.ifeline program.
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Time Is Muscle October 7, 2008:1216–21The D2B Alliance was developed to focus on improve-
ent in D2B times for patients with STEMI undergoing
rimary PCI. It is based on 6 core principles that have been
hown to shorten D2B (30). Approximately 1,000 hospitals
re participating in the D2B Alliance, the goal of which is
o achieve the recommended system goal D2B time of 90
in for at least 75% of nontransferred patients (30).
The AHA Mission: Lifeline program is a broad, compre-
ensive national initiative to improve the quality of care and
utcomes of patients with STEMI by improving health care
ystem readiness and response to STEMI (29). The Mission:
ifeline program will incorporate lessons learned from
uccessful vanguard systems of care efforts in the U.S. as well
s Europe on citywide, regional, and national levels (19,31–
6). Improvements in access to timely care for patients with
TEMI will require a multifaceted approach involving
atient education, improvements in the EMS and emer-
ency department components of care, the establishment of
etworks of STEMI-referral hospitals (not PCI capable)
nd STEMI-receiving hospitals (PCI capable), as well as
oordinated advocacy efforts to work with payers and policy
akers to implement much needed health care system
edesign (29). Clinicians caring for patients with STEMI
re encouraged to visit the new AHA Mission: Lifeline
ebsite and register their system—a vital step in this T3
hase effort.
By focusing now on system efforts for improvements in
imely care for STEMI, we will complete the cycle of
esearch initiated by Reimer and Jennings (6) 30 years ago.
ime is muscle . . . we must translate that into practice.
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